Oncology Based In-Vivo CRO Market Study Explores Industry Growth Toward $2.53 Billion

The oncology-based in-vivo CRO market is positioned for significant expansion as advancements in cancer research and drug development continue to accelerate. Increasing reliance on specialized contract research organizations to conduct complex in-vivo studies, along with technological innovations, are set to drive this market's growth over the coming years.

Oncology Based In-Vivo CRO Market Size and Growth Potential
The market for oncology-based in-vivo CROs is projected to reach $2.54 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.2%. This rapid expansion is fueled by growing interest in patient-derived xenograft (PDX) models, which better replicate human tumors in preclinical testing. Additionally, the integration of digital data management systems and the rise in personalized oncology drug development are key contributors. Outsourcing in-vivo studies to specialized CROs is increasing as pharma companies seek expertise and efficiency. The adoption of automated imaging and monitoring technologies further supports this upward trend. Notable market trends include the growing use of digital platforms for study management, AI and machine learning applications in preclinical oncology research, expanded genomic profiling for PDX models, enhanced automation in testing and data analytics, and the incorporation of IoT-enabled laboratory monitoring systems.

The oncology based in-vivo cro market size has grown rapidly in recent years. It will grow from $1.5 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing demand for preclinical oncology studies, growth of animal model-based research, rising prevalence of blood cancers and solid tumors, expansion of contract research organizations globally, increasing regulatory requirements for preclinical validation.

Download a free sample of the oncology based in-vivo cro market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Drivers Behind the Oncology Based In-Vivo CRO Market Growth
One of the main growth drivers is the rising demand for advanced patient-derived xenograft models, which improve the accuracy and relevance of oncology research. These models allow researchers to better simulate tumor behavior and drug responses, helping to streamline the development pipeline.
Another important factor boosting market expansion is the increasing adoption of automated imaging and monitoring technologies. These innovations enable more precise and efficient data collection during in-vivo studies, reducing errors and improving analysis quality. Furthermore, the digital transformation of study management processes is enhancing operational efficiency for CROs and their clients.

Top Companies Shaping the Oncology Based In-Vivo CRO Market
Several prominent players currently dominate the oncology-based in-vivo CRO landscape. These include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, and Biocytogen LLC.

View the full oncology based in-vivo cro market report:
https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Recent Developments Expanding Market Capabilities
In March 2023, ClinChoice Medical Development, a US-based CRO specializing in accelerating drug and device approvals, acquired Cromsource S.r.l., an Italian contract research organization. This acquisition broadens ClinChoice's operational footprint by adding new delivery hubs in Europe to complement its existing US network. It also enhances their data science technology offerings, particularly in risk-based monitoring and decentralized clinical trials, strengthening their service portfolio in oncology in-vivo research.

Emerging Trends in Oncology Based In-Vivo CRO Services
Leading companies in this sector are investing heavily in novel therapies such as CAR T-cell treatments to gain competitive advantages. CAR T-cell therapy, an innovative immunotherapy, modifies T cells to target and destroy cancer cells effectively.
For example, in May 2023, the Seattle Children's Hospital and Research Institute launched BrainChild Bio, a platform aimed at speeding up CAR T-cell therapies for pediatric brain tumors. Initially focusing on diffuse intrinsic pontine gliomas (DIPG), an incurable brainstem tumor in children, BrainChild Bio leverages synthetic biology to enhance CAR T-cell effectiveness against central nervous system cancers. The company plans to expand applications to other challenging brain tumors like glioblastoma and brain metastases once pediatric approvals are secured.

Segmentation Overview of the Oncology Based In-Vivo CRO Market
The market is divided into several key segments for analysis:
1) By Indication: Blood Cancer, Solid Tumors, and Other Indications
2) By Model Type: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), and Other Models
3) By End-User Application: Pharmaceutical or Biopharma Companies, Biotechnology Companies, Academic and Research Institutes, and CROs or Contract Research Partners

Further subcategories include:
- Blood Cancer types like Leukemia, Lymphoma, and Myeloma
- Solid Tumor types such as Breast Cancer, Lung Cancer, Colorectal Cancer, and Prostate Cancer
- Other Indications including Neuroblastoma, Germ Cell Tumors, and Sarcomas

Together, these segments provide a detailed picture of the oncology-based in-vivo CRO market's current structure and potential growth pathways.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.